KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Tax Provisions (2023 - 2025)

Historic Tax Provisions for Recursion Pharmaceuticals (RXRX) over the last 3 years, with Q3 2025 value amounting to $3000.0.

  • Recursion Pharmaceuticals' Tax Provisions fell 9820.36% to $3000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$148000.0, marking a year-over-year increase of 9715.22%. This contributed to the annual value of -$1.1 million for FY2024, which is 7225.5% up from last year.
  • Recursion Pharmaceuticals' Tax Provisions amounted to $3000.0 in Q3 2025, which was down 9820.36% from -$158000.0 recorded in Q1 2025.
  • Recursion Pharmaceuticals' 5-year Tax Provisions high stood at $167000.0 for Q3 2024, and its period low was -$4.1 million during Q4 2023.
  • Over the past 3 years, Recursion Pharmaceuticals' median Tax Provisions value was -$158000.0 (recorded in 2025), while the average stood at -$763571.4.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Tax Provisions surged by 10017.23% in 2024, and later crashed by 9820.36% in 2025.
  • Recursion Pharmaceuticals' Tax Provisions (Quarter) stood at -$4.1 million in 2023, then skyrocketed by 100.17% to $7000.0 in 2024, then plummeted by 57.14% to $3000.0 in 2025.
  • Its Tax Provisions stands at $3000.0 for Q3 2025, versus -$158000.0 for Q1 2025 and $7000.0 for Q4 2024.